Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population

Siba Raychaudhuri, Soumajyoti Sarkar, Saumya Panda, Byungsoo Kim, Smriti Raychaudhuri, Asutosh Ghosh

Research output: Contribution to journalReview article

Abstract

Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis. However, a major concern is that patients receiving this therapy have an increased risk of infection, particularly of reactivation of latent tuberculosis (TB). There were an estimated 10.4 million new cases of tuberculosis in 2016, worldwide, and India has one of the largest TB case burden with an estimated incidence of 2.79 million cases of TB in the same year. Anti-TNF agents like etanercept and infliximab are available in India approved for psoriasis and psoriatic arthritis. But long-term use of these agents possesses a risk of reactivation of latent TB. In this review article, we assessed the risk of TB with anti-TNF therapy especially in patients with psoriasis and psoriatic arthritis in India. At the end of the article, we have also suggested a recommendation for screening of latent tuberculosis and its management, before starting anti-TNF-α therapy.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalIndian Journal of Dermatology, Venereology and Leprology
Volume86
Issue number1
DOIs
StatePublished - Jan 1 2020

Keywords

  • Anti-tumor necrosis factor agents
  • latent tuberculosis
  • psoriasis
  • psoriatic arthritis

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population'. Together they form a unique fingerprint.

  • Cite this